

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.



Abbisko Cayman Limited

和譽開曼有限責任公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2256)

**VOLUNTARY ANNOUNCEMENT
ABBISKO THERAPEUTICS' LAVENGRATINIB (ABSK061)
FOR THE TREATMENT OF ACHONDROPLASIA GRANTED
ORPHAN DESIGNATION BY EMA**

Abbisko Cayman Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd. (“**Abbisko Therapeutics**”), a subsidiary of the Company, announced its proprietary selective orally available small-molecule FGFR2/3 inhibitor, lavengratinib (ABSK061), has been granted Orphan Designation (“**OD**”) by the European Medicines Agency (“**EMA**”) for the treatment of achondroplasia (“**ACH**”).

This is a voluntary announcement made by the Company. The Group cannot guarantee that ABSK061 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, 21 October 2026

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Ji Jing as executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Ms. Chui Hoi Yam as independent non-executive directors.

Abbisko Therapeutics' Lavengratinib (ABSK061) for the Treatment of Achondroplasia Granted Orphan Designation by EMA

On 21 October 2026, Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**") announced that its proprietary selective orally available small-molecule FGFR2/3 inhibitor, lavengratinib (ABSK061), has been granted Orphan Designation ("**OD**") by the European Medicines Agency ("**EMA**") for the treatment of achondroplasia ("**ACH**").

ACH is a rare, potentially life-threatening and debilitating growth disorder with limited treatment options currently available worldwide. The granting of the EMA Orphan Designation marks another important milestone in the international development of lavengratinib and further underscores its innovative potential and clinical value recognized by a leading international regulatory authority. Previously, lavengratinib for the treatment of ACH received both Orphan Drug Designation ("**ODD**") and Rare Pediatric Disease Designation ("**RPDD**") from the U.S. Food and Drug Administration ("**FDA**"), and its IND application has been cleared by the FDA. The successive designations granted by regulatory authorities in the U.S. and Europe provide robust momentum for lavengratinib to address the substantial unmet medical needs in ACH and advance its global development.

ACH is an autosomal dominant disorder primarily caused by mutations in the FGFR3 gene, which can lead to severe systemic skeletal developmental and ossification abnormalities and associated complications. Lavengratinib is a novel, orally available, highly potent and selective small-molecule inhibitor of FGFR2 and FGFR3 independently discovered by Abbisko Therapeutics. It leverages the Abbisko Therapeutics' unique oral mini-tablet formulation technology, with each tablet being less than 3 mm in diameter and allowing convenient administration with food and drink, potentially improving the convenience and adherence of long-term treatment for children with ACH.

Abbisko Therapeutics is currently advancing a Phase II, multicenter, open-label, dose-escalation study (ABSK061-202) of lavengratinib in children aged 3-12 years with ACH. Recent preliminary data demonstrated positive signals for growth promotion, with favorable overall safety and tolerability.

Abbisko Therapeutics will continue to advance the global clinical development of lavengratinib for ACH, further evaluate its safety and efficacy, and explore its potential to provide a new treatment option for children with ACH worldwide.

About Lavengratinib (ABSK061)

Lavengratinib is a novel, orally bioavailable, highly potent and selective small molecule inhibitor of FGFR2 and FGFR3 independently discovered and wholly-owned by Abbisko Therapeutics. It is the first FGFR2/3 inhibitor to enter clinical trials globally. First-generation pan-FGFR inhibitors demonstrated clinical efficacy in multiple tumors carrying FGFR2/3 variants and have steadily gained regulatory approval globally. However, the therapeutic window of pan-FGFRs and their clinical efficacy have been limited by side effects associated with FGFR1 inhibition. By reducing FGFR1 activity while maintaining potency against FGFR2 and FGFR3, lavengratinib is expected to achieve a wider therapeutic window with improved clinical efficacy as a new-generation of FGFR inhibitors. Lavengratinib for the treatment of achondroplasia has received both RPDD and ODD from the U.S. FDA, and its Phase II clinical trial is currently ongoing.

About Abbisko Therapeutics

Founded in 2016, Abbisko Therapeutics (HKEX: 02256) is a pharmaceutical company committed to the research, discovery, and development of innovative and differentiated medicines designed to address unmet medical needs in China and globally.

Adhering to international concepts and standards for drug development, Abbisko primarily centers on small molecules, emphasizing precision oncology and immuno-oncology, with a growing expansion into both non-oncology therapeutic areas and other modalities. Its self-developed Class 1 innovative drug, pimicotinib, has received approval from the China NMPA, while dozens of other candidates are currently in clinical development stages.

Abbisko Therapeutics is committed to creating first-in-class and best-in-class innovative drugs. Through an unwavering pursuit of scientific innovation, the company strives to provide transformative therapies with breakthrough efficacy for patients worldwide.

For more information, please visit www.abbisko.com.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.